Literature DB >> 19164917

Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease.

Rosanna Squitti1, Carlo C Quattrocchi, Carlo Salustri, Paolo M Rossini.   

Abstract

A dysfunction in copper homeostasis seems to occur in Alzheimer's disease (AD). We recently demonstrated that an excess of non-ceruloplasmin-copper (i.e., 'free' copper) correlates with the main functional and anatomical deficits as well as the cerebrospinal markers of the disease, thus suggesting that copper contributes to AD neurodegeneration. Aim of this study was to investigate the profile of serum ceruloplasmin isoforms immunoreactive protein in relation to copper dysfunction in AD. Twenty-five AD patients and 25 controls were included in the study. All subjects underwent individual measurements of serum ceruloplasmin and copper concentrations, and the amount of 'free' copper was computed for each copper and ceruloplasmin pair. Serum samples were also pooled and analyzed by two dimensional polyacrylamide gel electrophoresis (2-D PAGE) and western blot analysis. The mean concentration of 'free' copper resulted higher in AD patients than in controls. Ceruloplasmin 2-D PAGE western blot analysis of pooled sera showed in the AD samples low-molecular-weight spots in the <50 kDa range that were not detected in controls' pooled sera (p < 0.029). Our data indicate a ceruloplasmin fragmentation in the serum of AD patients, possibly related to 'free' copper deregulation in this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19164917      PMCID: PMC2634417          DOI: 10.4161/pri.2.1.6297

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  28 in total

1.  Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease.

Authors:  Frank-Gerald Pajonk; Holger Kessler; Tillmann Supprian; Pegah Hamzei; Daniela Bach; Janina Schweickhardt; Wolfgang Herrmann; Rima Obeid; Andreas Simons; Peter Falkai; Gerd Multhaup; Thomas A Bayer
Journal:  J Alzheimers Dis       Date:  2005-09       Impact factor: 4.472

2.  Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients.

Authors:  Concetta R Capo; Mario Arciello; Rosanna Squitti; Emanuele Cassetta; Paolo Maria Rossini; Lilia Calabrese; Luisa Rossi
Journal:  Biometals       Date:  2007-11-30       Impact factor: 2.949

3.  Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid.

Authors:  Dorothea Strozyk; Lenore J Launer; Paul A Adlard; Robert A Cherny; Andrew Tsatsanis; Irene Volitakis; Kaj Blennow; Helen Petrovitch; Lon R White; Ashley I Bush
Journal:  Neurobiol Aging       Date:  2007-12-18       Impact factor: 4.673

4.  Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease.

Authors:  H Kessler; F-G Pajonk; P Meisser; T Schneider-Axmann; K-H Hoffmann; T Supprian; W Herrmann; R Obeid; G Multhaup; P Falkai; T A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

5.  Elevated cortical zinc in Alzheimer disease.

Authors:  D Religa; D Strozyk; R A Cherny; I Volitakis; V Haroutunian; B Winblad; J Naslund; A I Bush
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

6.  Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau.

Authors:  R Squitti; G Barbati; L Rossi; M Ventriglia; G Dal Forno; S Cesaretti; F Moffa; I Caridi; E Cassetta; P Pasqualetti; L Calabrese; D Lupoi; P M Rossini
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

7.  Excess of serum copper not related to ceruloplasmin in Alzheimer disease.

Authors:  R Squitti; P Pasqualetti; G Dal Forno; F Moffa; E Cassetta; D Lupoi; F Vernieri; L Rossi; M Baldassini; P M Rossini
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

8.  Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers.

Authors:  C González; T Martín; J Cacho; M T Breñas; T Arroyo; B García-Berrocal; J A Navajo; J M González-Buitrago
Journal:  Eur J Clin Invest       Date:  1999-07       Impact factor: 4.686

Review 9.  Structure to function relationships in ceruloplasmin: a 'moonlighting' protein.

Authors:  P Bielli; L Calabrese
Journal:  Cell Mol Life Sci       Date:  2002-09       Impact factor: 9.261

10.  'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function.

Authors:  R Squitti; M Ventriglia; G Barbati; E Cassetta; F Ferreri; G Dal Forno; S Ramires; F Zappasodi; P M Rossini
Journal:  J Neural Transm (Vienna)       Date:  2007-07-04       Impact factor: 3.575

View more
  8 in total

1.  Copper phenotype in Alzheimer's disease: dissecting the pathway.

Authors:  Rosanna Squitti; Renato Polimanti
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

2.  Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Authors:  Richard J Perrin; Rebecca Craig-Schapiro; James P Malone; Aarti R Shah; Petra Gilmore; Alan E Davis; Catherine M Roe; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Jeffrey A Kaye; John C Morris; David M Holtzman; R Reid Townsend; Anne M Fagan
Journal:  PLoS One       Date:  2011-01-12       Impact factor: 3.240

3.  Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease.

Authors:  Serena Bucossi; Stefania Mariani; Mariacarla Ventriglia; Renato Polimanti; Massimo Gennarelli; Cristian Bonvicini; Patrizio Pasqualetti; Federica Scrascia; Simone Migliore; Fabrizio Vernieri; Paolo M Rossini; Rosanna Squitti
Journal:  Int J Alzheimers Dis       Date:  2011-06-15

4.  Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease.

Authors:  Gudlaug Torsdottir; Jakob Kristinsson; Jón Snaedal; Torkell Jóhannesson
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-11-05

5.  Effects of microcystin-containing cyanobacterial extract on hematological and biochemical parameters of common carp (Cyprinus carpio L.).

Authors:  Anna Sieroslawska; Anna Rymuszka; Josef Velisek; Barbara Pawlik-Skowrońska; Zdenka Svobodova; Tadeusz Skowroński
Journal:  Fish Physiol Biochem       Date:  2012-01-07       Impact factor: 2.794

6.  Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia.

Authors:  Alan Zanardi; Antonio Conti; Marco Cremonesi; Patrizia D'Adamo; Enrica Gilberti; Pietro Apostoli; Carlo Vittorio Cannistraci; Alberto Piperno; Samuel David; Massimo Alessio
Journal:  EMBO Mol Med       Date:  2018-01       Impact factor: 12.137

Review 7.  Molecular Functions of Ceruloplasmin in Metabolic Disease Pathology.

Authors:  Zhidong Liu; Miao Wang; Chunbo Zhang; Shigao Zhou; Guang Ji
Journal:  Diabetes Metab Syndr Obes       Date:  2022-03-03       Impact factor: 3.168

8.  Neocortex and allocortex respond differentially to cellular stress in vitro and aging in vivo.

Authors:  Jessica M Posimo; Amanda M Titler; Hailey J H Choi; Ajay S Unnithan; Rehana K Leak
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.